Subscribe To

Price Alert Latest News Economic Calendar News

MBRX / Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

HOUSTON , Sept. 8, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will virtually present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, NY September 8-10, 2022. Read More

Demo Live Account See Partner Details

Content Topics

Moleculin

Selected

Present

Annual

Marie

Sklodowska

Curie

Sklodowska curie

Symposium

Cancer

Research

Stock

MBRX

Posted: Sep 8 2022, 08:45

Author Name: PRNewsWire

MBRX News

By Zacks Investment Research
September 22, 2023

Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up

Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarco

By InvestorPlace
September 15, 2023

Why Is Moleculin Biotech (MBRX) Stock Is Moving Today?

Moleculin Biotech (NASDAQ: MBRX ) stock is on the move Friday after the clinical-stage pharmaceutical company provided an update to investors. Accord

By PRNewsWire
September 5, 2023

Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

HOUSTON , Sept. 5, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical compan

By Seeking Alpha
August 11, 2023

Moleculin Biotech, Inc. (MBRX) Q2 2023 Earnings Call Transcript

Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q2 2023 Earnings Call Transcript August 11, 2023 8:30 AM ET Company Participants Jenene Thomas - IR Walter Klem

By PRNewsWire
August 3, 2023

Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast

HOUSTON , Aug. 3, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company

By PRNewsWire
June 13, 2023

Moleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Live webcast fireside chat on Wednesday, June 21 st at 1:30 PM ET HOUSTON , June 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Mo

By Seeking Alpha
May 11, 2023

Moleculin Biotech, Inc. (MBRX) Q1 2023 Earnings Call Transcript

Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Jenene Thomas - Investor Relation

By InvestorPlace
May 11, 2023

MBRX Stock Earnings: Moleculin Biotech Misses EPS Estimates

Moleculin Biotech (NASDAQ: MBRX ) reported first quarter results for 2023. Moleculin Biotech reported a loss per share of 28 cents.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.